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Abstract
Objectives—To determine the extent to which initial therapy for nonmetastatic prostate cancer 
was concordant with nationally recognized guidelines using supplemented cancer registry data and 
what factors were associated with receipt of nonguideline-concordant care.
Methods—Initial therapy for 8229 nonmetastatic prostate cancer cases diagnosed in 2004 from 
cancer registries in 7 states was abstracted as part of the Centers for Disease Control’s Patterns of 
Care Breast and Prostate Cancer study conducted during 2007 to 2009. The National 
Comprehensive Cancer Network clinical practice guidelines version 1.2002 was used as the 
standard of care based on recurrence risk group and life expectancy (LE). A multivariable model 
was used to determine risk factors associated with receipt of nonguideline-concordant care.
Results—Nearly 80% with nonmetastatic prostate cancer received guideline-concordant care for 
initial therapy. Receipt of nonguideline-concordant care (including receiving either less aggressive 
therapy or more aggressive therapy than indicated) was related to older age, African American 
race/ethnicity, being unmarried, rural residence, and especially to being in the high recurrence risk 
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group where receiving less aggressive therapy than indicated occurred more often than receiving 
more aggressive therapy (adjusted OR = 4.2; 95% CL, 3.5–5.2 vs. low-risk group). Compared 
with life table estimates adjusted for comorbidity, physicians tended to underestimate LE.
Conclusions—Receipt of less aggressive therapy than indicated among high-risk group men 
with >5-year LE based on life table estimates adjusted for comorbidity was a concern. Physicians 
may tend to underestimate 5-year survival among this group and should be alerted to the 
importance of recommending aggressive therapy when warranted. However, based on more recent 
guidelines, among those with low-risk disease, the proportion considered to be receiving less 
aggressive therapy than indicated may now be lower because active surveillance is now 
considered appropriate.
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Factors affecting initial prostate cancer treatment selection include life expectancy (LE), 
clinical stage, prostate-specific antigen (PSA) level, Gleason score, comorbidities1; effects 
of treatment on quality of life2; physician recommendations, and personal values.3 
Treatment alternatives are commonly divided between conservative therapy (ie, androgen 
deprivation therapy [ADT], watchful waiting, and, more recently, active surveillance [AS]) 
and aggressive therapy (including radical prosta-tectomy [RP], external beam radiation 
therapy [EBRT], bra-chytherapy [BT], or combinations of these therapies).4
Because of the wide range of options for treatment and the role of patient and physician 
preference, the National Comprehensive Cancer Network (NCCN) clinical practice 
guidelines for prostate cancer treatment are recommendations that “represent a current 
consensus regarding acceptable approaches to prostate cancer treatment, rather than a 
universally prescribed course of therapy” (NCCN 2002).5 The guideline goals are to 
optimize cancer survival while minimizing treatment-related morbidity, thus physicians may 
use independent judgment when developing treatment plans.
The Institute of Medicine (IOM) recommended that population-based cancer registries be 
used for assessing quality of cancer care and examining variations in standards of care.6 This 
is also an IOM goal for comparative effectiveness research.7 In response, the National 
Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention 
(CDC) funded the Breast and Prostate Cancer Data Quality and Patterns of Care Study 
(POC-BP). One of the aims was to determine the extent to which care received was 
concordant with nationally recognized treatment guidelines and here we report on the 
findings related to prostate cancer treatment.
MATERIALS AND METHODS
Sample Selection and Data Collection
Conducted in 2007 to 2009, the POC-BP study included cases diagnosed in 2004 from 7 
states, including 6 statewide cancer registries in Georgia, Kentucky, Louisiana, Minnesota, 
North Carolina, and Wisconsin, as well as regional registries in southern California 
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(including Los Angeles and San Bernardino counties).8 The study involved supplementation 
of cancer registry data with reabstraction of medical records from hospitals and some 
outpatient facilities. Information on the demographic characteristics of the patient, clinical 
characteristics of the tumor, workup procedures, and the first course of cancer-directed 
treatment (ie, therapy that was given or planned at the time of initial cancer diagnosis, before 
disease recurrence or progression) was collected. The POC-BP data were linked with the 
2000 US Census to obtain residential indicators. The study was approved or exempted by 
institutional review boards at participating institutions from the 7 states and the CDC.
From all participating registries, 11,679 cases of invasive prostate cancer (International 
Classification of Diseases for Oncology, 3rd ed, codes C61.9) were randomly selected 
across strata defined by race/ethnicity and state-specific factors such as Appalachian region, 
type of facility, or patient volume of the facility. Each case was the first primary cancer for 
the patient except for the previous diagnoses of basal or squamous cell carcinomas of the 
skin, benign brain tumors, or lymphohematopoietic malignancies diagnosed before 2001. 
Cases diagnosed at Veteran’s Administration hospitals were excluded,9 as were cases 
identified through death certificates or at autopsy, and those with a diagnosis of a subsequent 
cancer within 4 months. On the basis of records available when the reabstraction was done, 
77.2% (9017/11,679) of the selected cases were reabstracted. About 13% of the reabstracted 
cases had missing data for ≥1 of the approximately 300 variables in the study; and when 
available, the original abstracted value was included for these missing values. After 
eliminating 33 who died within 6 months after diagnosis, 178 with missing stage 
information, and 577 with advanced disease, 8229 with nonmetastatic disease were included 
in these analyses. These cases included those with a T stage of T0, T1, or T2, excluding 
those with any positive lymph nodes or distant metastases.
Comorbidity Definition
The Adult Comorbidity Evaluation-27 (ACE-27) was selected to measure comorbidity 
burden because it is specific for cancer and has a dose-response relationship to survival.10–13 
It is based on 26 comorbid conditions with 3 grades of decompensation (or severity) and 
excludes complications of cancer or its treatment. An overall comorbidity severity score 
(none, severe, moderate, or mild) was determined by the highest ranking single condition,11 
unless the subject had at least 2 moderate comorbidities in different body systems when the 
grade was coded as severe.
Estimation of LE
Because LE is a major factor for determination of guideline care, we asked physicians to 
provide an estimate of the patient’s LE using intervals that were relevant to the NCCN 
guidelines (ie, <5, 5 to 9, 10 to 19, and 20 +). However, because physicians were not 
contacted for all patients or did not provide an estimate, this information was available for 
only 5.3% of the total. Thus, we determined the remaining years of life based on a man’s 
age at diagnosis from standard US life tables in 2004 for whites and African Americans,14 
and adjusted it using the ACE-27 comorbidity severity score, similar to the method 
described in the NCCN guidelines.4 As the life table reflects the average number of 
remaining years of life among all men in the subgroup of the population it is based on, it is 
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likely that those with better health would be expected to live longer than this average, 
whereas those with poorer health may be expected to live a shorter time than the average. To 
take a man’s health into account, we increased the number of remaining years obtained from 
the life table by multiplying it by 1.5 for those in the quartile with the lowest comorbidity 
severity scores (ie, those with the fewest comorbidities), and reduced life table estimate of 
remaining years by multiplying it by 0.5 for those in the highest quartile of the comorbidity 
severity scores (ie, those with the worst health). No change was made in the life table 
estimates for those with comorbidity severity scores in the middle 2 quartiles.
Definitions of Initial Therapies
Initial therapies received within 6 months after diagnosis were grouped into major categories 
to assess overall patterns of care, including RP (regardless of other therapy received), BT, 
EBRT (including 2D-XRT, 3D-CRT, and IMRT), combination of EBRT + BT ( ± ADT), 
primary ADT (PADT), and no therapy (NT) within the 6 months after diagnosis (AS, if 
there was specific mention of surveillance, watchful waiting, or monitoring and NT, 
otherwise).
A more detailed categorization used to assess guideline care was based on single versus 
combination therapies. Single therapies included: RP, EBRT, BT, radiotherapy type 
unknown (RTunk), PADT, and AS or NT. Combination therapies were defined as: RP + 
ADT, RP + EBRT/RTunk, RP + EBRT/RTunk + ADT, EBRT + ADT, BT + ADT, EBRT + 
BT, EBRT + BT + ADT, and RTunk + ADT.
Prostate Cancer Guideline Care Definition
The guidelines for therapy were based on the version 1.2002 of the NCCN Clinical Practice 
Guidelines in Oncology,4 which were in place in 2004 (Appendix 1). Guideline care was 
based on LE categories (< 5, 5 to 9, 10 to 19, and 20 + y) and NCCN risk of recurrence 
group (restricted to localized, nonmetastatic disease):
a. Recurrence risk low (T1 to T2a and Gleason score 2 to 6 and PSA < 10 ng/mL).
b. Recurrence risk intermediate (T2b to T2c OR Gleason score 7 OR PSA 10 to 20 
ng/mL).
c. Recurrence risk high (T≤3 AND Gleason score 8 to 10 OR PSA > 20 ng/mL).
Receipt of guideline care was categorized as guideline concordant or guideline discordant 
which was categorized as follows: (1) had more aggressive therapy than indicated, (2) had 
less aggressive therapy than indicated, and (3) had PADT when the options were either 
observation or surgery/radiation therapy.
Demographic, Residential, and Clinical Variables
Specific categories for all variables are shown in Table 1. The demographic variables 
included age, race/ethnicity, marital status, and health insurance. Area-based measures were 
constructed from 2000 US Census data linked to the census tract of the patient’s residence 
and included percent of the population that was in an urban area, percent in the working 
class, percent below the federal poverty level, and percent of adults (above 25 y old) without 
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a high school education. A 3-level socioeconomic status (SES) index was based on the 
poverty level and educational attainment variables: high (poverty level <20% and percent 
without a high school degree <25%), middle (with one of the indicators in these ranges), and 
low (with neither indicator in these categories).15 Clinical variables included clinical stage at 
diagnosis, PSA which was the highest value prior and closest to the initiation of treatment, 
Gleason score, comorbidity severity score, and NCCN Recurrence Risk Group as previously 
defined.
Statistical Methods
Both univariate and multivariable methods were used to identify factors associated with 
receipt of guideline care for initial therapy for those with nonmetastatic. The χ2 tests were 
used to determine univariate differences and multivariable logistic regression modeling was 
used to estimate significant independent predictors of use of guideline-discordant care, 
including variables that were significant at P < 0.10 from the univariate results. The results 
of the logistic regression analyses were expressed as adjusted odds ratios (ORs) with 95% 
confident limits (CL). All results were weighted based on the sampling fraction to provide 
results that represented the source population of the sampled cases using SAS Proc Survey-
Logistic and SAS Proc SurveyFreq.
RESULTS
Just over a quarter of the prostate cases were younger than 60 years and between 17% and 
20% were in each of the other age categories (Table 1). Nearly 3 quarters of subjects were 
non-Hispanic white (NHW), 17% were African American, over 6% were Hispanic, and <3% 
were Asian or other. Just over 60% had a form of private insurance (including Medicare + 
private), whereas 27% had Medicare alone or other public insurance. The proportions 
residing in each of the 7 states ranged from 7.4% to 24.6%. Half lived in an area classified 
as urban, and 15% lived in census tracts with the lowest SES ranking based on income and 
education.
Just over one third had no comorbidities. The most common stage at diagnosis was T1 
(64%), 60% had a PSA between 4 and 10 ng/mL, and close to 53% had a Gleason score 
between 2 and 6. Over 41% of these nonmetastatic cases were in the low recurrence risk 
group, another 42% were in the intermediate risk group, and just under 17% were in the 
high-risk group.
LE
The effect of the comorbidity adjustment of LE varied by age group (Fig. 1). Among those 
below 60 years of age at diagnosis, 98% had a ≥20 years LE based on the standard life tables 
and after adjustment for comorbidity severity 96% did so. Among those 60 years old or 
over, the comorbidity adjustment resulted in no change or a greater proportion was shifted to 
an increased LE than to reduced LE.
We compared the physicians’ estimates of patient’s LE to the adjusted life table estimates 
for 476 cases and found low to moderate agreement beyond what would be expected by 
chance (κ = 0.28, percent agree = 50%) for the major categories required for NCCN 
Hamilton et al. Page 5
Am J Clin Oncol. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
treatment decisions (ie, <5 y, 5 to 9 y, 10 to 19, and 20 + y). Compared with the adjusted life 
table–based estimates, physicians were more likely to underestimate than to overestimate LE 
by a ratio of 2.5:1.
Initial Treatment
Among men with nonmetastatic prostate cancer, almost 80% received some form of 
aggressive therapy: 43.6% received RP (as a single therapy or in combination with other 
therapies), 19.9% received EBRT (alone), and 16.0% received BT (with or without EBRT) 
(Table 2). Those receiving conservative therapy included 6.9% with PADT, 4.7% with AS, 
and 9.0% with NT. Age at diagnosis was a major factor related to therapy choice, with RP 
being the most common therapy within each age group under 70. EBRT was the most 
common therapy among those 70 and over. Over 20% of men 65 to 74 years received BT, 
whereas nearly half of men 75 + years received a type of conservative therapy. NHW were 
the most likely to receive RP (46%), whereas African Americans were the least likely 
(36%). African Americans and Asians were more likely to receive EBRT than NHW and 
Hispanics. NHW had the highest proportion receiving BT (16.9%) compared with the other 
racial/ethnic groups.
The proportion receiving RP varied from 55% to 34% among the 7 states participating, 
whereas use of BT ranged from 28.2% to 9.9%. Men living in census tracts with the high 
SES index were more likely to have RP, whereas use of PADT or NT occurred more often 
in the low SES tracts.
Among the clinical variables, those with none or lower comorbidity severity, lower T stage, 
and lower PSA group were more likely to receive RP than those within higher levels of 
these variables. However, those with a Gleason score of “7” were more likely to receive 
surgery compared with those with lower or higher scores, as were those in the intermediate 
NCCN risk group compared with those in the low-risk or high-risk groups. There were 
contrasting patterns for the use of EBRT and BT (alone or with EBRT). Those with 
clinically more advanced disease (based on stage, PSA, Gleason score, and risk group) were 
more likely to receive EBRT than those within lower levels of these variables. BT was more 
often used among the low-risk group than in the high-risk group (23% vs. 7.6%). Similarly, 
PADT was used more often among those with higher PSA, Gleason score, and risk group 
categories, whereas AS and NT were more often used among those within lower categories 
of these variables.
Assessment of Receipt of Guideline Care for Initial Therapy
After applying the criteria used to assess receipt of NCCN guideline care based on risk 
group and LE, 79.2% of men with nonmetastatic disease received guideline-concordant care, 
6.3% had more aggressive therapy than indicated, 12.5% had less aggressive therapy than 
indicated, and 2.0% received PADT when it was not indicated (Table 3).
When RP ( ± ADT) was received as a sole therapy for localized disease, 99% of the time it 
was considered concordant with NCCN guidelines; however, it was considered more 
aggressive treatment than indicated when combined with radiation therapy (Table 3). 
Similarly, sole use of EBRT or BT ( ± ADT) was considered guideline concordant for 94% 
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to 97% of those receiving it; however, the combination of EBRT + BT ( ± ADT) which was 
only recommended for those with intermediate risk, was considered more aggressive 
treatment than indicated for close to half of the patients receiving both of these therapies. 
Most guideline-discordant care occurred among those receiving PADT with 68.2% receiving 
less aggressive therapy than indicated and 28.6% receiving it when either AS/NT or RP/
EBRT was indicated. In addition, among those with AS/NT, 54% were deemed to have 
received less aggressive therapy than indicated.
On the basis of a multivariable logistic regression model, age at diagnosis, race/ethnicity, 
marital status, urban/rural residence, comorbidity severity, and NCCN risk group were 
independent predictors of guideline-discordant care (Table 4). Men 75 years of age or older 
were over twice as likely to receive guideline-discordant care (especially less aggressive 
therapy than indicated) than those under the age of 60 (adjusted OR, 2.3; 95% CL, 1.9–2.9). 
African American and unmarried men were 40% more likely to receive guideline-discordant 
care than men in their respective reference groups. Those in the intermediate risk group were 
less likely to receive guideline-discordant care compared with low-risk group men (adjusted 
OR, 0.8; 95% CL, 0.7–0.9); however, men in the high-risk group were over 4 times as likely 
to receive guideline-discordant care (particularly less aggressive therapy) compared with 
those in the low-risk group (adjusted OR, 4.2; 95% CL, 3.5–5.2).
DISCUSSION
Overall we found that the NCCN guidelines in place in 2004 were broad enough so that 
nearly 80% of nonmetastatic cases were guideline concordant in initial treatment, based on 
recurrence risk group and estimated LE. Among the non-metastatic cases deemed guideline 
discordant, the majority received less aggressive therapy than indicated. Although these 
guidelines define a consensus of expert opinion for treatment, they may not always provide 
the best approach for treating individual patients who may have preferences related to 
quality of life and specific treatment effects.16 Men may wish to avoid the substantial 
treatment effects associated with aggressive therapy and there is lack of definitive evidence 
regarding the survival benefit of treatment. Recently 15-year survival data from the Prostate 
Cancer Outcomes Study (PCOS) showed that men older than 60, with low or intermediate 
risk disease and >3 comorbidities, would have a higher probability of death from other 
causes and would not have a survival benefit from receiving surgery or radiation.17 
Likewise, a study based on Medicare data found that a greater number of comorbidities were 
associated with decreased survival with adjustment for treatment having little impact.18 In 
contrast, a study based on Surveillance, Epidemiology, and End Results (SEER)-Medicare 
data for men diagnosed between 1991 and 1999 found a survival benefit associated with 
surgery or radiation therapy among men with low/intermediate risk disease, using a 
propensity score to adjust for confounding factors, including comorbidities.19
If a man has high-risk disease and 5 + years of LE, aggressive therapy is usually considered. 
PCOS data were used to compare long-term quality of life differences between surgery and 
radiation and found that there were no statistically significant differences after 15 years of 
follow-up.20 However, additional analyses of this same dataset, also using propensity scores 
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to adjust for confounding factors, suggest that surgery may be associated with a better long-
term survival than radiation therapy, especially among younger men.21
The overall patterns of care for nonmetastatic prostate cancer that we observed in this 
registry-based study involving 7 states in 2004 were very similar to a study of 14 SEER 
program registries in 2002.22 In each study the proportion of men treated by RP was close to 
44%, 20% received EBRT, and 16% to 18% received BT ( ± EBRT). We found a slightly 
lower proportion receiving PADT (7% vs. 8.5%) and a higher proportion with AS/NT 
(13.7% vs. 9.0%).
We identified important disparities in the receipt of guideline care for nonmetastatic disease, 
particularly among those in the high recurrence risk group who were over 4 times as likely 
to receive guideline-discordant care (especially less aggressive therapy) compared with 
those in lower recurrence risk groups, and among older men 75 + who were over twice as 
likely to receive guideline-discordant care, compared with those below 60 years of age. In 
addition, African American men were 40% more likely to receive guideline-discordant care 
compared with white men, which was also indicated in the previous SEER-based study.22
There have been significant changes in the NCCN guidelines since 2004.23 Among low 
recurrence risk men, the percentage with guideline-concordant care would likely be higher 
now because AS is now an option for low-risk men with 10 + years of LE and 20% of those 
classified as receiving less aggressive therapy than indicated would now be guideline 
concordant. Likewise the combination of EBRT + BT for high-risk men is now considered 
guideline-concordant care, and 77% of those men categorized as receiving more aggressive 
therapy than indicated would be reclassified to guideline concordant.
One of the most critical criteria for determining NCCN guideline care is estimated LE. 
Among a small sample, we found that physicians were more likely to underestimate 
remaining years of life than to overestimate them compared with the life table estimates 
adjusted for comorbidity scores. Other studies have indicated that life table estimates, even 
when adjusted for comorbidity, tend to overestimate LE, whereas physician estimates may 
be more accurate,24 especially in determining if the patient has under or over 10 years to 
live.25 The accuracy of physician estimates of ± 5 years, however, is less certain. If 
physicians are underestimating 5-year survival, some men with high recurrence risk may not 
be receiving appropriate therapy. The subgroup of most concern was the nonmetastatic cases 
within the high recurrence risk group, where 32.6% received less aggressive therapy than 
indicated. These were cases with a >5-year LE (adjusted life table estimate) who received 
AS/NT or PADT, when aggressive therapy was indicated.
Limitations of this study include the sole use of inpatient medical records for some cases, 
when outpatient records were not available or were not sought when guideline care was 
determined from hospital records. Care received in the out-patient setting, particularly use of 
hormones and radiation therapy, has been shown to be underreported in registry data 
compared with claims information.26 In addition, despite the efforts to enhance registry data, 
men classified as receiving NT may be missing data on therapy received.27 The results are 
limited to the 2004 diagnosis year and thus do not reflect current guideline-based care. 
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However, future efforts to use registry data to assess guideline care may be hampered by 
lack of data necessary to identify very low-risk disease (eg, number of positive biopsy cores, 
maximum percent positive within a core, and PSA density)27 although this information may 
be available through linkage with other databases. Finally, estimates of LE based on life 
tables and comorbidity may result in overestimates of LE compared with physician 
estimates.
In summary, we found that the majority of men with nonmetastatic disease were treated 
according to consensus-based NCCN guideline standards, and although the proportion may 
be even higher if current standards were applied, the disparities in guideline treatment that 
we found may be indicative of subgroups at higher risk of receiving guideline-discordant 
care in general. Receipt of less aggressive therapy than indicated among high-risk group 
men with >5-year LE based on life table estimates adjusted for comorbidity was a concern. 
Physicians may tend to underestimate 5-year survival among this group and should be 
alerted to the importance of recommending aggressive therapy when warranted.. It would be 
important to assess physician accuracy at estimating 5-year survival in comparison with 
actual survival experience. Although these standards are based on a consensus of expert 
opinion, the final decision for treatment of a man with prostate cancer will ultimately depend 
on personal preferences and his specific clinical characteristics.
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Initial Therapy
The recommended initial therapy is based on recurrence risk and LE.
A. Recurrence risk low (T1 to T2a and Gleason score 2 to 6 and PSA < 10 ng/mL).
Estimation of LE
1. Less than 10 years: Observation or radiation therapy (3D-CRT or BT).
2. 10 to 20 years: Observation or radiation therapy (3D-CRT or BT) or radical 
prostatectomy with/without pelvic lymph node dissection.
3. > 20 years: Radical prostatectomy with/without pelvic lymph node 
dissection or radiation therapy (3D-CRT or BT).
B. Recurrence risk intermediate (T2b to T2c OR Gleason score 7 OR PSA 10 to 20 
ng/mL).
Estimation of LE
1. Less than 10 years: Observation or radiation therapy (3D-CRT and/or BT) or 
radical prostatectomy with/without pelvic lymph node dissection.
2. > 10 years: Radical prostatectomy with/without pelvic lymph node 
dissection or radiation therapy (3D-CRT and/or BT).
C. Recurrence risk high (localized) (T≤3 AND Gleason score 8 to 10 OR PSA > 20 
ng/mL).
Estimation of LE
1. Less than 5 years: Observation or androgen ablation.
2. > 5 years: Androgen ablation (2 to 3 y) + radiation therapy (3D-CRT) OR 
radiation therapy (3D-CRT) for selected patients with Gleason score of <7 
and PSA < 10 ng/mL OR radical prostatectomy with pelvic lymph node 
dissection for selected patients with low volume and no fixation.
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FIGURE 1. 
Percent distribution of years of life expectancy remaining calculated from life table and 
adjusted for comorbidity by age group at diagnosis: CDC POC BP Study.
Hamilton et al. Page 12
Am J Clin Oncol. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Hamilton et al. Page 13
TABLE 1
Demographic, Residential, and Clinical Characteristics of Men Diagnosed With Nonmetastatic Prostate 
Cancer, 2004, CDC Breast and Prostate Patterns of Care Study
Variables Total Sample Weighted %
8229 100.00
Demographic
 Age group at diagnosis
  < 60 2169 26.2
  60–64 1444 17.5
  65–69 1681 20.3
  70–74 1390 17.1
  75 + 1545 18.8
 Race/ethnicity
  White 4822 73.6
  Black 2444 17.4
  Hispanic 570 6.5
  API/AI/AN 393 2.5
 Marital status
  Married 5965 74.1
  Single/Divorced/Separated/Widowed 1794 20.1
  Unknown 470 5.8
 Insurance
  Private 4787 60.6
  Medicaid 600 5.6
  Medicare, other public insurance 2326 27.1
  None 134 1.4
  Unknown 382 5.3
 State
  A 1467 24.6
  B 1729 16.3
  C 494 7.4
  D 1618 10.0
  E 918 11.9
  F 989 18.2
  G 1014 11.6
Residential (census tract)
 Urbanization
  Urban 3985 50.4
  Rural 1313 14.2
  Urban-rural mix 2900 35.0
  Unknown 31 0.4
 Working class
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Variables Total Sample Weighted %
  < 66% in working class 3322 46.0
  66 + % in working class 4875 53.6
  Unknown 32 0.4
 Poverty level
  < 20% in poverty 6185 82.4
  20 + % in poverty 2012 17.2
  Unknown 32 0.4
 Educational attainment
  < 25% without HS education 5026 68.0
  25 + % without HS education 3171 31.6
  Unknown 32 0.4
 Socioeconomic status
  Low 1776 15.1
  Middle 1631 18.5
  High 4790 65.9
  Unknown 32 0.4
Clinical variables
 Comorbidity severity
  None 2667 34.1
  Mild 4091 48.4
  Moderate 887 10.4
  Severe 309 3.8
  Unknown 275 3.3
 Stage
  Tx-T0 224 2.6
  T1 5275 64.1
  T2 2730 33.3
 PSA
  < 4 901 11.7
  4–10 4824 60.2
  > 10 2075 23.3
  Unknown 429 4.8
 Gleason Score
  2–6 4249 52.8
  7 2946 35.0
  8–10 956 11.3
  Unknown 78 0.9
 NCCN risk group
  Low-complete data 2966 38.1
  Low-incomplete data* 273 3.2
  Intermediate 3491 41.8
  High 1499 16.9
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*
T1-2a and either PSA < 10 OR Gleason Score <7 with the other variable unknown.
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